Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An investigation of Levetiracetam in Alzheimer's Disease (ILiAD)
2016-003109-32Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of levetiracetam in Alzheimer's disease (AD), sponsored by University of Oxford. Primary endpoint: Primary Outcome: Changes in cognition via hippocampal binding memory task. Status: unknown.
02
Drugs
levetiracetam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-003109-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003109-32.